20 stories about Pharmaceuticals
צוות Nucleai מימין לוטן חורב אלירון אמיר אבי ויידמן אלברט אכטרברג

The Israeli startup using spatial biology to provide better cancer treatment

02.01.22|Yafit Ovadia
Nucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions
David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
גלעד רדאי

Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms

28.02.21|Yafit Ovadia
Israeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
מימין תומר קריב ו רן נוסבאום מנהלי קרן פונטיפקס

Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold

12.10.20|Tzally Greenberg
A series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis
קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

What’s behind the timed resurgence of lawsuits against Teva?

28.08.20|Sophie Shulman
The Israeli pharmaceutical giant was hit with three legal blows over the course of a few days
מוסף שבועי 16.4.20 פרופ' רגינה ברזילי

Hitting the Reset Button on Antibiotics

17.04.20|Viki Auslender
As the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment
אסטרהזנקה חברת תרופות מטה בריטניה astrazeneca

Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel

27.11.19|Meir Orbach
Alongside funding, the program will provide Israeli startups with mentorship and training
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Quarterly Report Meets Analyst Expectations

07.11.19|Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
מטה חברת טבע תרופות

Teva Overcomes One Hurdle, Many Still Ahead

23.10.19|Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
אתר טבע כפר סבא

Teva to Close Missouri Plant, Report Says

29.08.19|Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
קאר שולץ מנכל טבע

Rivals' Earning Reports Should Have Teva's Shareholders Worried

05.08.19|Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
אתר טבע כפר סבא

Teva to Pay California $69 Million in Narcolepsy Drug Settlement

30.07.19|Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
מוסף שבועי 18.7.19 ד"ר שחר ברבש

Paving the Way to Alzheimer’s Cure, One Algorithm at a Time

19.07.19|Tzipi Smilovitz
Israeli scientist Shahar Barbash is making waves in the pharmaceutical world with a new approach to image analysis that has even chemistry Nobel laureate Michael Levitt on board
אורי קליד פאי תרפיוטיקס Pi Therapeutics

Pi Therapeutics Raises $19.7 Million

29.05.19|Hagar Ravet
Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
מטה חברת טבע תרופות

Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition

28.05.19|Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
רפואה בריאות רפואי תרופות מחקר

Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement

Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
מוסף רפואה מבחנה מבחנות תרופה תרופות בית חולים

Can-Fite BioPharma to Raise $3.2 Million in Direct Offering

The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer